XML 68 R48.htm IDEA: XBRL DOCUMENT v3.20.4
Collaborative Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 01, 2021
Apr. 11, 2018
Dec. 31, 2017
Dec. 29, 2017
Jun. 30, 2020
Apr. 30, 2020
Mar. 31, 2020
Jan. 31, 2020
Aug. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Oct. 31, 2018
Mar. 31, 2018
Sep. 30, 2015
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2018
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Total revenues                             $ 5,580,581 $ 236,178 $ 267,187 $ 1,327,274 $ 279,488 $ 866,863 $ 135,673 $ 2,829,905   $ 7,411,220 $ 4,111,930 $ 30,481,897
Revenues                             5,580,581 236,178 267,187 1,327,274 279,488 866,863 135,673 2,829,905   7,411,220 4,111,930 30,481,897
Deferred grant funding                             7,474,310       6,065,212         7,474,310 6,065,212  
Revenue under collaborative research and development arrangements                                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Total revenues                             5,003,494 21,490 74,102 71,500 184,523 617,427 64,283 2,770,712   5,170,586 3,636,945 29,860,785
Revenues                             5,003,494 $ 21,490 $ 74,102 $ 71,500 $ 184,523 $ 617,427 $ 64,283 $ 2,770,712   5,170,586 3,636,945 29,860,785
Advaccine                                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Total revenues                                               5,000,000.0    
Revenues                                               5,000,000.0    
Advaccine | Collaborative Arrangement                                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Upfront payment received                                               3,000,000.0    
Additional revenue to be achieved                                               108,000,000.0    
Collaboration agreement, payment earned                                               $ 2,000,000.0    
Obligation period to pay royalties                                               10 years    
Agreement period from effective date for termination                                               1 year    
Total revenues                                               $ 5,000,000.0    
Revenues                                               5,000,000.0    
Advaccine | Collaborative Arrangement | Revenue under collaborative research and development arrangements                                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Total revenues                                               5,000,000.0    
Revenues                                               5,000,000.0    
Advaccine | Collaborative Arrangement | Subsequent Event                                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Upfront payment received $ 3,000,000.0                                                  
ApolloBio | Collaborative Arrangement                                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Upfront payment received                         $ 23,000,000.0                   $ 23,000,000.0 23,000,000.0   $ 23,000,000.0
Additional revenue to be achieved                                               $ 20,000,000.0    
Obligation period to pay royalties                                               10 years    
Agreement period from effective date for termination                                               1 year    
Territory expansion option period       3 years                                            
Proceeds from collaborative agreement                         19,400,000                          
Advisory fees                         960,000                          
Agreement, number of days written notice before termination                                               90 days    
ApolloBio | Collaborative Arrangement | Foreign Tax Authority                                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Collaborative agreement, corporate income tax                         2,200,000                          
Collaborative agreement, foreign non-income Taxes                         $ 1,400,000                          
AstraZeneca | Collaborative Arrangement                                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Upfront payment received     $ 27,500,000                     $ 27,500,000                        
Agreement anticipated development and regulatory event based payment receivable milestones                                               $ 125,000,000    
Agreement, anticipated commercial event based payment receivable milestones                                               115,000,000    
Agreement, milestone payment, revenue recognized                   $ 2,000,000.0 $ 2,000,000.0                              
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement                                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Upfront payment received                                               6,400,000 6,300,000  
Collaborative agreement, funding to be received   $ 56,000,000       $ 6,900,000                                        
Collaborative agreement, period to receive funding for research and development   5 years                                                
Deferred grant funding                             2,600,000                 2,600,000    
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | COVID19 Vaccine                                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Collaborative agreement, funding to be received               $ 9,000,000.0                               10,000,000.0    
Deferred grant funding                             3,400,000                 3,400,000    
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | IN O4800                                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Collaborative agreement, funding to be received           1,300,000                                        
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device                                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Collaborative agreement, funding to be received           $ 5,000,000.0                                        
Bill And Melinda Gates Foundation | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device                                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Collaborative agreement, funding to be received             $ 5,000,000.0                                 4,100,000    
Deferred grant funding                             884,000                 884,000    
Bill And Melinda Gates Foundation | Collaborative Arrangement | D N A Encoded Monoclonal Antibody Technology                                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Collaborative agreement, funding to be received                 $ 1,100,000     $ 2,200,000                       463,000 $ 2,100,000  
Deferred grant funding                             575,000                 575,000    
Department Of Defence | Collaborative Arrangement                                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Collaborative agreement, funding to be received         $ 54,500,000                                          
Grant proceeds received                                               21,200,000    
Accounts receivable                             $ 11,400,000                 $ 11,400,000    
Department Of Defence | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device                                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                    
Purchase price, procurement contract         $ 16,600,000